What does it mean to compare two stocks in a single page?

Comparing two stocks on one page helps readers see how each company structures its business, earns revenue, and performs financially within the same market context. It highlights differences in sector, profitability, growth drivers, and valuation, while remaining neutral and educational. In this comparison, Oscar Health and Lazard are assessed using available performance data and market conditions.

How should I read ‘pros and cons’ for each stock?

Pros and cons summarise strengths and potential risks identified in the context of the company’s business model and market. They are not forecasts, but indicators of what investors might consider important, such as earnings trends, valuation concerns, and market sensitivity. Use them to weigh potential upside against possible downsides for each stock.

What does a high price-to-earnings or price-to-book ratio imply in this comparison?

Price-related multiples reflect how the market values a company relative to earnings or book value. A higher ratio may indicate higher growth expectations or overvaluation, while a lower ratio could signal undervaluation or risk. In this page, Oscar Health’ and Lazard’s ratios help readers gauge valuation against peers and magnitude of potential upside or risk.

Why is ‘growth vs. profitability’ important when comparing winners and losers?

Growth measures revenue expansion potential, while profitability looks at earnings efficiency. Oscar Health may show revenue growth drivers but ongoing losses, whereas Lazard emphasises diversified revenue streams and capital returns. Balancing growth prospects with profitability helps readers understand sustainability and risk in pursuing future returns.

How should I interpret ‘analyst consensus’ and target prices in this page?

Analyst consensus reflects average recommendations and price targets from experts, offering a market-coloured view. If targets imply limited upside or downside, it signals balanced or cautious expectations. Remember, targets are opinions and subject to change with new information or market conditions.

What market conditions influence the performance of these two stocks?

Oscar Health operates in health insurance and technology-enabled services, so regulatory shifts and healthcare demand affect it. Lazard’s business relies on advisory activity and asset flows, which respond to macroeconomic cycles and investor appetite. Both are sensitive to broader financial conditions and capital markets trends.

How does cyclicality affect this two-stock comparison?

Cyclicality refers to how revenue and earnings respond to economic cycles. Advisory and asset management activity can rise with confidence and capital markets strength; fall during downturns. Insurance-related tech adoption may persist, but earnings dynamics can still be cyclical due to cost and utilisation trends.

What does ‘revenue diversification’ mean in this comparison?

Revenue diversification describes multiple sources of income, reducing reliance on a single stream. In this page, Lazard benefits from both financial advisory and asset management, while Oscar Health relies more on its technology platform and health insurance operations. Diversified revenues may support resilience in varied market environments.

Is this page a recommendation guide, or a neutral educational resource?

This page is designed as a neutral educational resource. It compares business models, performance and market context without suggesting buy or sell actions. Users should consider their own objectives, risk tolerance, and perform further analysis before making investment decisions.

Educational disclaimer for readers

Educational disclaimer: The content presents a structured comparison of Oscar Health and Lazard based on publicly available information provided in this page. It is not financial advice, nor an encouragement to buy or sell. Readers should consult a licensed adviser for personalised guidance.

Oscar Health vs Lazard

Oscar Health is a tech-driven health insurer chasing profitability in the individual market, while Lazard is a century-old financial advisory firm monetizing relationships at the top of global M&A and restructuring. They're both navigating fee-intensive business models, but that's where the similarities end. The Oscar Health vs Lazard comparison breaks down how growth trajectory, margin structure, and revenue predictability differ across these two distinct financial services plays.

Oscar Health is a tech-driven health insurer chasing profitability in the individual market, while Lazard is a century-old financial advisory firm monetizing relationships at the top of global M&A and...

Comparison Snapshot

Key Financial Metrics

OSCR

Metric

LAZ

$4.95B

Market Cap

$4.42B

-4.13%

Potential Profit

12.60%

Hold

Analyst Rating

Hold

Discover More Comparisons

Oscar Health vs Selective

Oscar Health bets its future on tech-driven health insurance for individuals while Selective Insurance has spent over a century quietly compounding in the commercial property-casualty market. Both operate within the broader insurance industry, but their risk profiles, customer bases, and growth trajectories are miles apart. The Oscar Health vs Selective comparison reveals which insurer delivers more compelling financials and whether Oscar's disruptive model can match Selective's proven underwriting discipline.

Oscar Health vs Upstart

Oscar Health sells individual and small-group health insurance plans powered by its own technology platform while Upstart uses AI to underwrite personal and auto loans at a pace that traditional lenders can't match, pairing two data-driven financial platforms that took very different paths through the rising-rate environment. Both companies raised capital aggressively during low-rate conditions and had to reckon sharply with investor skepticism when macro conditions shifted. Oscar Health vs Upstart lays out the loss ratio trends, unit economics evolution, and path to sustainable profitability that define whether either company's growth thesis has actually matured.

Oscar Health vs Lemonade

Oscar Health built a tech-forward health insurance platform targeting individual and small-group markets with a digital-first member experience, while Lemonade set out to reinvent property and casualty insurance with AI-driven claims processing and a B-Corp charitable giving model. Both are insurtech companies that raised enormous amounts of capital on the promise that technology could make insurance faster, cheaper, and less adversarial, yet both have faced hard questions about underwriting losses and the path to profitability. The Oscar Health vs Lemonade comparison puts two high-profile insurance disruptors side by side to see whose loss ratios, growth rates, and capital runway tell a more convincing story about eventual viability.

Investment Analysis

Oscar Health

OSCR

Pros

Oscar Health has demonstrated strong technology-driven differentiation through its proprietary platform, which supports engagement and operational efficiency in the health insurance market.
The company has shown resilience in a challenging sector, with recent quarterly results beating earnings expectations despite ongoing losses.
Oscar Health maintains a relatively low price-to-sales ratio compared to sector peers, suggesting potential value if revenue growth accelerates.

Considerations

Oscar Health continues to report net losses, with negative earnings per share indicating ongoing profitability challenges in a competitive insurance landscape.
The stock trades at a high price-to-book ratio relative to sector averages, raising concerns about valuation sustainability.
Analyst consensus suggests significant downside risk, with average price targets indicating a negative upside compared to current levels.

Lazard

LAZ

Pros

Lazard has delivered record adjusted net revenue and strong year-on-year growth in both financial advisory and asset management segments in 2025.
The firm has maintained robust asset inflows and expanded its asset management business, supporting long-term revenue diversification.
Lazard continues to return capital to shareholders through dividends and share repurchases, reflecting financial discipline and confidence in its balance sheet.

Considerations

Recent share price volatility reflects sensitivity to global investment demand and broader financial sector risks, which could impact near-term performance.
Analyst consensus is neutral, with average price targets suggesting limited upside potential from current levels.
Growth in advisory revenue is closely tied to macroeconomic conditions and M&A activity, making results cyclical and exposed to market downturns.

Related Market Insights

Private Market Liquidity: Could Goldman's Move Signal a Shift?

Goldman Sachs' acquisition of Industry Ventures highlights the booming private market liquidity and venture capital secondary market. Explore investment opportunities in this evolving financial landscape.